APODDC

111 posts

APODDC banner
APODDC

APODDC

@apoddc

We’ll be hosting Clinical Trial Design webinars in 2023! Follow us to be kept up to date. 📊🧑🏻‍💻

Beigetreten Haziran 2022
64 Folgt86 Follower
APODDC retweetet
Herbert Loong, MBBS, FASCO
Herbert Loong, MBBS, FASCO@herbloong·
📢 #Happy to share w/ #LCSM community! After 3+ years of work, we are pleased to share our #cost_effectiveness modelling for #lungcancer 🫁 #screening 🏥📸 in both #high-risk populations determined by both #smoking & #non-smoking risk factors e.g. family history for an entire community. Taking #hongkong 🇭🇰 as an example of our #EastAsia region w/ specific lung cancer #epidemiology and #molecularcharacteristics, we have shown that #ICER for high risk individuals based on factors not associated with smoking is even lower. This is the first study of modelling for an entire health system catering for both high risk groups. This calls for #government & other #stakeholders to push forward #territorywide #lungcancer screening for ALL #highrisk individuals - regardless of smoking history. Further details can be found here: jtocrr.org/article/S2666-… @CarlosWongHKU @mollylisc @CUHKMedicine @hkumed @HKU_D24H @IASLC @APCLC_2023 @apoddc @LungPolicy #NELSON #TALENT #PublicHealth
Herbert Loong, MBBS, FASCO tweet media
English
2
9
27
2.5K
APODDC retweetet
ESMO Open
ESMO Open@ESMO_Open·
Safety of tarlatamab with 6-8h outpatient vs 48-h inpatient monitoring during C1: DeLLphi-300 ph1 substudy in @ESMO_Open. Outpatient monitoring feasible, same CRS rate, most managed w/o hospitalization/ER visit. Anticipate&monitor AEs in educated pts is🔑. esmoopen.com/article/S2059-…
ESMO Open tweet media
English
1
12
34
3.7K
Hidehito HORINOUCHI
Hidehito HORINOUCHI@HHorinouchi·
🌟 #JSMO25 @JSMO_official 🇯🇵 📸 Nice to see Dr. Pei Jye Voon 🔝5⃣ @JTOonline REVIEWER🏆 🎉Congratulations🎊 #LCSM @OncoAlert
Hidehito HORINOUCHI tweet media
IASLC@IASLC

🏅 Cheers to the Top 5 JTO CRR Reviewers of 2024! 🏅 Your dedication advances lung cancer research—thank you! 👏 Paolo Bironzo, Nicolas Girard, William Evans, Hidehito Horinouchi, Pei Jye Voon 🔹 Apply for the 2025 Reviewer Workshop by April 1: bit.ly/ReviewerWS #WCLC25

English
1
0
11
1.1K
APODDC retweetet
Hidehito HORINOUCHI
Hidehito HORINOUCHI@HHorinouchi·
🔥 @JCO_ASCO 🆙 ✅LIBRETTO-001 final: Selpercatinib in RET Fusion–Positive Non–Small Cell Lung Cancer 🎯mOS 47.6 (pretreated pts), not reached (treatment-naïve) 👥 @GautschiOliver #LCSM @OncoAlert
OncoAlert@OncoAlert

Selpercatinib in RET Fusion–Positive Non–Small Cell Lung Cancer #NSCLC 🫁 : Final Safety and Efficacy, Including Overall Survival, From the LIBRETTO-001 Phase I/II Trial buff.ly/YlqitQJ This phase I/II study evaluating selpercatinib in RET fusion-positive non–small cell #Lungancer (NSCLC) saw Final results with durable efficacy, an objective response rate (ORR) of 62% in patients who had prior platinum-based chemotherapy and 83% in treatment-naïve patients. The duration of response (DoR) was 31.6 months and 20.3 months, respectively, and progression-free survival (PFS) was 26.2 months for pretreated and 22.0 months for treatment-naïve patients. At 3 years, 57% of pretreated and 66% of treatment-naïve patients were alive. Selpercatinib also demonstrated an 85% ORR in patients with CNS metastases. @GautschiOliver @bensolomon1 @herbloong @geoff_oxnard @alexdrilon

English
1
18
51
6.1K
APODDC retweetet
Stephanie Saw
Stephanie Saw@stephanieplsaw·
Delighted to share our review paper on ADCs in NSCLC with AGA is out! Very timely given the anticipated data readouts this year. Such an honour to be a part of this awesome team, special thanks to @g_mountzios and @JordiRemon for leading this 🙌🏻
Giannis Mountzios@g_mountzios

Biomarker-selected or biomarker-agnostic ADCs for oncogene-addicted #NSCLC❓ 💡Just out in @myESMO #CancerTreatmentReviews a comprehensive overview on current landscape, challenges and perspectives Grateful to work with a global amazing team, including @stephanieplsaw @HendriksLizza @JessicaMenis Tina Cascone @ogarrieta @DrJNaidoo @Alfdoc2 @peters_solange and senior author @JordiRemon Link to the Review:👇 doi.org/10.1016/j.ctrv…

English
3
20
64
5.4K
APODDC retweetet
Brian Van Tine
Brian Van Tine@bvantine1·
It's ok at #CTOS2024 to drag me to your poster to pitch your science for Clinical Cancer Research, it the most inspiring thing i get to do!!
English
2
4
50
1.9K
APODDC retweetet
Herbert Loong, MBBS, FASCO
Herbert Loong, MBBS, FASCO@herbloong·
Thanks @drkiwicj @drkiwikate @anmwongNZ @cameroncologist #DaisyMak (who needs to get on Twitter! 😆) & all my other 🇳🇿 #oncology friends @NzsOncology for your invitation & hospitality. Amazing talks & discussions throughout the conference. Perfect forum to build collaborations. @ASCO #InternationalAffairsCommittee @IASLC #LCSM #Sarcoma @CUHKMedicine #CUHKSarcoma @apoddc @APCLC_2023 #precisiononcology @OncoAlert
Prof. Chris Jackson@drkiwicj

What a privilege to have an academic of the quality of @herbloong speaking at @NzsOncology on precision oncology. Kia Ora Herbert!

English
0
3
22
1.5K
APODDC
APODDC@apoddc·
📢Announcement: Join us at our 1st #APODDCForum2024 where we discuss about the Regulatory Harmonisation for Oncology Clinical Trials & Therapeutics Registration in the APAC Region📷 Sign up now via lnkd.in/gDPsHNib!📧 More details on our LinkedIn Page!
APODDC tweet media
English
0
0
0
146
APODDC retweetet
Rashid Lui 雷諾信
Rashid Lui 雷諾信@RashidLui·
Prof Jacky Lam sharing at the @CUHKMedicine Department of Clinical Oncology Academic Meeting on liquid biopsy for early cancer detection #oncology
Rashid Lui 雷諾信 tweet media
English
0
2
17
1.5K

Entdecken

@CarlosWongHKU @mollylisc @CUHKMedicine @hkumed @IASLC @APCLC_2023 @LungPolicy @ESMO_Open